Trial Profile
A Phase II Study of IPI-504, a Novel Hsp90 Inhibitor, in NSCLC Patients With ALK Translocations.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Retaspimycin (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms SEQUIST-TBD
- 01 Feb 2012 Planned end date changed from 1 Oct 2012 to 1 Feb 2012 as reported by ClinicalTrials.gov.
- 01 Feb 2012 Planned end date changed from 1 Oct 2012 to 1 Feb 2012 as reported by ClinicalTrials.gov.
- 01 Feb 2012 Actual patients number is 4 as reported by ClinicalTrials.gov.